Early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting predicts cancer-specific survival in metastatic castrate-resistant prostate cancer - Ahmed, ME; Lee, MS; Mahmoud, AM (Prostate Cancer Prostatic Dis, 2023)